|
The
FAP Gene Support Group
Was pleased to promote the following trial now closed
Seeking
FAP Patients for Phase
III Clinical Trial
Sponsor
The
trial is being sponsored by Cancer Prevention Pharmaceuticals,
Inc
Cancer
Prevention Pharmaceuticals, Inc. is developing novel therapeutic
agents, diagnostics, and lifestyle recommendations that make
possible the treatment of risk factors for cancer. Our clinical
focus is in familial adenomatous polyposis, neuroblastoma
and the prevention of recurrence in colon cancer survivors.
If
you are an FAP patient or know someone who is, you may be
interested in a clinical trial that is recruiting participants
in the United Kingdom, Germany, Spain, and the Netherlands,
United States and Canada
Following
Link Opens in New Window
Link to Trial Scroll down page for Contacts
Study
Objective
This
study will determine if a combination drug treatment works
better than each drug alone in preventing FAP disease progression.
It will also explore if the treatment can alter the course
of the disease and determine how the combination impacts quality
of life.
Eligibility
Patients
may be eligible if they have FAP and
- Have
not had their colon removed, but are considering this surgery
or,
- Have
advanced disease in the upper intestine or,
- Have
advanced disease in the pouch/rectum
If
they meet one of those requirements, they may be eligible
if:
- They
have a mutation in the APC gene. (If a patient has not been
previously tested, their blood will be checked at the study
site to determine if they are a carrier of the gene mutation.)
- Are
at least 18 years old
Treatment
& Study Duration
The
study explores two investigational oral medications: eflornithine
and sulindac. All participants will receive at least 1 active
drug. Participants will take 4 pills once a day for up to
2 years. It has been shown in several studies to reduce the
growth of colon polyps but has not been approved by the FDA
or EMA for this indication.
Additional
Information
For
additional trial information please go to:
Following
Links Open in New Window
http://canprevent.com/faptrial
or
https://clinicaltrials.gov
Identifier:
NCT01483144
|
